Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity by Rabinowitz, J. E. et al.
JOURNAL OF VIROLOGY,
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.2.791–801.2002
Jan. 2002, p. 791–801 Vol. 76, No. 2
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Cross-Packaging of a Single Adeno-Associated Virus (AAV)
Type 2 Vector Genome into Multiple AAV Serotypes
Enables Transduction with Broad Specificity
Joseph E. Rabinowitz,1 Fabienne Rolling,2 Chengwen Li,1 Hervè Conrath,2
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The serotypes of adeno-associated virus (AAV) have the potential to become important resources for clinical
gene therapy. In an effort to compare the role of serotype-specific virion shells on vector transduction, we
cloned each of the serotype capsid coding domains into a common vector backbone containing AAV type 2
replication genes. This strategy allowed the packaging of AAV2 inverted terminal repeat vectors into each
serotype-specific virions. Each of these helper plasmids (pXR1 through pXR5) efficiently replicated the
transgene DNA and expressed helper proteins at nearly equivalent levels. In this study, we observed a
correlation between the amount of transgene replication and packaging efficiency. The physical titer of these
hybrid vectors ranged between 1.3  1011 and 9.8  1012/ml (types 1 and 2, respectively). Of the five serotype
vectors, only types 2 and 3 were efficiently purified by heparin-Sepharose column chromatography, illustrating
the high degree of similarity between these virions. We analyzed vector transduction in reference and mutant
Chinese hamster ovary cells deficient in heparan sulfate proteoglycan and saw a correlation between trans-
duction and heparan sulfate binding data. In this analysis, types 1 and 5 were most consistent in transduction
efficiency across all cell lines tested. In vivo each serotype was ranked after comparison of transgene levels by
using different routes of injection and strains of rodents. Overall, in this analysis, type 1 was superior for
efficient transduction of liver and muscle, followed in order by types 5, 3, 2, and 4. Surprisingly, this order
changed when vector was introduced into rat retina. Types 5 and 4 were most efficient, followed by type 1. These
data established a hierarchy for efficient serotype-specific vector transduction depending on the target tissue.
These data also strongly support the need for extending these analyses to additional animal models and human
tissue. The development of these helper plasmids should facilitate direct comparisons of serotypes, as well as
begin the standardization of production for further clinical development.
The adeno-associated viruses (AAV) are members of the
family Parvoviridae and the genus Dependovirus. Serotypes 1 to
4 were originally identified as contaminates of adenovirus
preparations (5), whereas type 5 was isolated from a patient’s
wart that was human papillomavirus positive. To date, seven
molecular clones have been generated representing the sero-
types of AAV (2, 8, 9, 30, 34, 39, 46). These clones have
provided valuable reagents for studying the molecular biology
of serotype-specific infection. Transduction of these viruses
naturally results in latent infections, with completion of the life
cycle requiring helper functions not associated with AAV viral
gene products. As a result, all of these serotypes are classified
as nonpathogenic and are believed to share a safety profile
similar to the more extensively studied AAV type 2 (AAV2) (5).
The extensive development of AAV2 as a vector has been
facilitated by 30 years of studying its biology in vitro. Recom-
binant AAV2 (rAAV2) has proven to be a suitable gene trans-
fer vector in many different organisms (28, 32). As the number
of applications involving gene transfer increases in vitro and in
vivo, limitations to efficient rAAV2 transduction have become
apparent (3, 11, 18, 37, 41, 46, 49). The natural tropism of any
virus, including rAAV2, is a fundamental limitation to efficient
gene transfer. With the identification of the AAV2 receptor,
the requirements for efficient entry in target cells have become
a critical topic of study (40). Efforts have been made to over-
come these restrictions by broadening the host range by using
either bispecific antibodies to the virion shell (4) or through
capsid insertional mutagenesis (13, 45). While these efforts are
beginning to bear fruit, utilizing the other serotypes of AAV
may yet provide additional resources for making safe efficient
gene transfer vectors. To this end, a small number of studies
have begun to show the utility of serotype-specific vectors in
vitro and in vivo (6, 8, 10, 11, 16, 20, 46, 49). In general, each
of these studies uncovered broader cell type specificity with
increased gene transfer in vivo. Additional efforts to separate
the role of the serotype-specific vector components (cis-acting
terminal repeats [TRs] and the trans-acting virion shell) will
not only facilitate a comprehensive understanding of efficient
vector transduction but will potentially allow the generation of
optimized new hybrid AAV vectors (i.e., AAV5 TRs packaged
in AAV1 shells).
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In an effort to evaluate the role of AAV1 to -5 virion shells
on AAV2 transgene transduction, a series of hybrid vectors
were designed. Each AAV serotype-specific helper construct
contained a high-yield plasmid backbone, the p5 start site mu-
tation ACG (25), removal of the adenovirus terminal repeats
(35, 36), and the ability to package transgenes utilizing AAV2
inverted terminal repeats (ITRs). These helper plasmids were
characterized in vitro for replication and capsid proteins, abil-
ity to replicate vector transgene, total particle number, and
purification by heparin-Sepharose chromatography (50). In ad-
dition, each hybrid serotype vector was compared for trans-
duction efficiency in both reference and proteoglycan mutant
Chinese hamster ovary (CHO) cell lines (40) and in vivo in
muscle, liver, and neuronal specific targets.
MATERIALS AND METHODS
Plasmids. The plasmid pBS (Stratagene) was used as the backbone for
cloning AAV serotypes 1 to 5 capsid genes. The AAV2 replication gene was
subcloned into the plasmid pAAV2Cap (31) by using a XbaI (blunt ended) SwaI
digestion of pACG2 (25), and a SmaI/SwaI digestion of pAAV2Cap. This new
plasmid, pAAV2rep, was digested with NaeI, blunt ended with mung bean
nuclease, and then digested with SwaI, removing the capsid gene and leaving only
the replication gene of AAV2. Viral sequences for AAV1, -2, -3, -4, and -5 were
cloned from American Type Culture Collection (ATCC) stocks. Primers were
designed for each of these serotypes, such that a SwaI site was present before the
coding region of Vp1 and a unique NotI site was present after the polyadenyl-
ation site. The forward primers were AAV1 and -2 (5-AAATCAGGTATGGC
TGCCGAT-3), AAV3 (5-AAATCAGGTATGGCTGCTGAT-3), AAV4 (5-
AAATCAGGTATGGCTGCTGACGGTTAC-3), and AAV5 (5-AAATCAG
GTATGGCTTTTGTTGATCAC-3). The reverse primers were AAV1, -2, -3,
and -4 (5-GCGGCCGCGAGACCAAAGTTCAACTGA-3) and AAV5 (5-G
CGGCCGCAAGAGGCAGTATTTTACTGA-3). Pfu polymerase (Stratagene)
was used in the PCR to generate the serotype-specific clones with blunt ends.
These serotype-specific capsid coding fragments were then cloned into
pAAV2rep. A BstNI digestion was used to confirm the presence and orientation
of the positive clones (Fig. 1B). Individual clones were chosen after testing for
virus production by using the triple transfection technique (26, 47). Clones
containing AAV3, -4 and -5 capsid genes and AAV2 replication gene did not
yield high-titer viruses from cell lysates or cesium gradients (Table 1). For clones
containing the serotype 3, 4, and 5 capsid gene, a portion of the serotype-specific
replication gene was substituted for that of AAV2. The AAV3 serotype clone
was digested with AccI, as was the original plasmid (nucleotides 1424 to 4355 of
the AAV3 sequence, Fig. 1A). The AAV4 serotype clone was digested with AccI
and AgeI, as was the original plasmid (nucleotides 1479 to 4488 of the AAV4
sequence, Fig. 1A). The AAV5 serotype clone was digested with BamHI, as was
the original plasmid (nucleotides 1071 to 2726 of the AAV5 sequence, Fig. 1A).
These clones were designated pXR1, -2, -3, -4, and -5. Plasmid pTR/CMV/GFP
(enhanced green fluorescent protein [EGFP] transgene) contains AAV2 ITRs
flanking a cytomegalovirus (CMV) immediate-early promoter driven EGFP
transgene (16); pXX6-80, a plasmid containing adenovirus genes required for
AAV production plasmid, was a gift from X. Xiao, and the plasmid pCB-AAT
was provided by Terry Flotte.
Cell culture. All cell lines (293 human embryonic kidney, HeLa, Cos7, Cos1,
CHO K1, and CHO K1 mutant deficient in proteoglycan biosynthesis [pgsA,
pgsD, and pgsE]) were originally obtained from the ATCC and were maintained
in 5% CO2 saturation at 37°C. 293, HeLa, Cos1, and Cos7 cells were cultured in
Dulbecco modified Eagle medium (DMEM) with 10% fetal bovine serum (Sig-
ma), and CHO K1 and CHO K1 proteoglycan-deficient lines were cultured in
F-12 nutrient mixture (Ham) with 10% fetal bovine serum.
Production of serotype-specific recombinant AAV. Transfection protocols as
previously described (31) were used with the following modifications. At 24 h
prior to transfection, 10- to 15-cm-diameter plates were seeded with 1.2  107
293 cells and transfected by Superfect (Qiagene) according to manufacturer’s
specifications by using the three-plasmid transfection technique (26, 47).
Equimolar amounts of each plasmid—75 g of pTR/CMV/GFP, 150 g of
pXX6-80 (adenovirus helper plasmid), and 75 g of the serotype-specific plas-
FIG. 1. Construction and characterization of serotype clones. (A) Each serotype capsid domain, generated by PCR, was cloned into the pBS
AAV2rep plasmid. The serotype-specific capsid insertions (shaded rectangles) were inserted into pBS AAV2rep and are listed in order from type
1 to 5. Restriction sites are shown in the AAV2 diagram. Additionally, modifications containing the coding region of the carboxy termini of each
serotype’s rep coding domain (gray hatched) were cloned into the constructs as needed. (B) Acrylamide gel of AAV serotypes 1 through 5 digested
with BstNI. White arrowheads point to common bands in the backbone and replication gene. The 50-bp ladder (Amersham Pharmacia) flanks the
serotype lanes.
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mids pXR1, -2, -3, -4, or -5—were mixed with 7 ml of DMEM without serum and
antibiotics and 1.2 ml of the SuperFect reagent before addition to cells. At 48 h
posttransfection, the cells were harvested and virus was isolated as previously
described (31). To each milliliter of viral supernatant, 0.59 g of CsCl was added,
and 1.38 g of CsCl/ml was added to a final volume of 12 ml. The solution was
centrifuged for 36 to 48 h at 37,000 rpm (Sorvall Ultra 80). Peak fractions from
the isopycnic gradient were determined by infection of HeLa cells except for
AAV4, which was tested on Cos1 cells. A second gradient (Beckman NVT-65
rotor at 65,000 rpm for 4 h) was incorporated for further purity, and peak
fractions were determined by infection and dot blot hybridization as described
below. Positive fractions were extensively dialyzed against Dulbecco phosphate-
buffered saline (PBS) without calcium or magnesium chloride (Gibco-BRL) and
supplemented with 10% (wt/vol) D-sorbitol (Sigma).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blots.
Protein samples from transfected human embryonic Kidney cells 293 were lysed
as described previously (31), and an aliquot was removed, to which phenylmeth-
ylsulfonyl fluoride at 100 g/ml (Sigma), pepstatin A at 1 g/ml (Sigma), and
leupeptine at 2 g/ml (Sigma) were added. Protein concentrations were esti-
mated by BCA Protein Assay (Pierce). Equivalent amounts of protein (5 g/
lane) from each serotype cell lysate were fractionated on a 10% denaturing
polyacrylamide gel and then transferred to Hybond ECL (Amersham Pharmacia
Biotech). Primary monoclonal antibodies 1F11 (22) and B1 (a gift from Jurgen
Kleinschmidt) were used to detect AAV Rep and capsid proteins, respectively, as
previously described by using SuperSignal West Pico (Pierce) for the detection of
secondary antibody conjugate.
Hirt DNA analysis from AAV serotype transfections. DNA from AAV sero-
type transfected 293 cells 24 h posttransfection was isolated by using the method
described by Hirt (21). Approximately half of each sample was digested with
DpnI enzyme, and 2.5 g of digested and undigested DNA was fractionated on
a 0.8% agarose gel. After transfer the blot was probed with a packaged transgene
(GFP), the positive signal was visualized by using a phosphorimager, and the
intensity of the bands was determined by image quantification.
Heparin column. After the five serotypes were purified by two rounds of
cesium chloride isopycnic centrifugation, dialyzed in 1 PBS (Gibco-BRL) plus
10% sorbitol with three changes, an equal amount of virus was injected into 1 ml
of a HiTrap heparin column (Amersham Pharmacia Biotech) by using Amer-
sham Pharmacia Biotech AKTA fast-performance liquid chromatography. A
preset program (12 ml of buffer at 137 mM NaCl, 2 mM MgCl2, and 2 mM KCl
run over the column at 0.5 ml/min for the flowthrough and wash, followed by a
waste wash of 10 ml of the same buffer at 1 ml/min) was implemented before
elution. The elution step used a continuous salt gradient from 137 mM NaCl2 to
1 M NaCl2 at a rate of 0.5 ml/min. For the flowthrough, wash, and elution steps,
0.5-ml fractions were collected, with the waste step collected in a single fraction.
Transducing units (TU)/microliter were determined for each fraction by trans-
ducing either HeLa (AAV1, -2, -3, and -5) or Cos1 cells (AAV4) in triplicate.
The titer of the input virus was also determined so that a percentage of the
recovered TU to the total number could be calculated.
Dot blot. Dot blots were performed essentially as described previously (31).
Briefly, 2 to 10 l of virus from fractions off the cesium gradient, after dialysis,
or the heparan column was blotted to GeneScreen Plus by using a dot blot
manifold, and then the GeneScreen was UV cross-linked at 60 mJ (UV Strata-
linker 1800; Stratagene). Finally, the blot was hybridized for positive signal by
using GFP probe.
In vitro transduction assay. Cell lines were infected with rAAV serotypes by
using a volume of virus equivalent to 105 TU. For each datum point at least three
experiments were performed, and the average is presented. The titers of the
AAV serotypes 1, 2, 3, and 5 were originally determined on HeLa cells, and that
of AAV4 was determined on Cos1 cells (reference cell lines). Between 1  105
and 1.75  105 cells of each cell type were plated in 24-well plates 24 h prior to
infection. The volume of each serotype equivalent to 105 TU was added to 100
l of DMEM that included adenovirus, and this was added to each well dropwise.
After 24 h the number of GFP-positive cells was counted. Eight fields/well were
counted, and the average number of GFP-positive cells/well was determined; this
number was then multiplied by the dilution to obtain the number of TU/micro-
liter.
ELISA analysis of factor IX and 1-antitrypsin. NOD/Scid, BALB/c, and
C57/BL mice were purchased form Jackson Laboratories (Bar Harbor, Maine).
Mice were maintained and treated in accordance with the Animal Care and Use
Committee of University of North Carolina at Chapel Hill. Portal vein injection,
for liver expression, and muscular injection were performed as previously de-
scribed (6). NOD/Scid mice were each injected with 2  1011 particles, and
BALB/c mice were each injected with 1010 particles of the rAAV serotypes
containing the canine factor IX transgene (6). Canine factor IX antigen was
detected by enzyme-linked immunosorbent assay (ELISA) as previously de-
scribed (H. J. Chao et al., unpublished data). Both BALB/c and C57/BL mice
were each injected with 5  1010 particles of rAAV serotypes containing the
human 1-antitrypsin transgene. A modified double-antibody sandwich ELISA
was used for measurement of 1-antitrypsin in biologic fluids (27).
Subretinal injection and in vivo fluorescence imaging. Subretinal injections
were performed via a transcleral transchoroidal approach on wild-type Wistar
rats as previously described (33). Briefly, the sclera and the choroid were punc-
tured; a 33-gauge needle was then inserted in a tangential direction under an
operating microscope. Then, 3 l of each of the five hybrid rAAV serotypes (5 
1011 particles/ml) was delivered into the subretinal space (n  3, for each
serotype). A new method with fundus photography has been developed and
performed in order to control the accuracy and reproducibility of subretinal
injections (F. Rolling et al., unpublished data).
GFP protein expression in live rats was monitored by fluorescent retinal
imaging by using a Canon UVI retinal camera connected to a digital imaging
system (Lhedioph Win Software). Retinas were examined at 12, 26, and 46 days
postinjection.
RESULTS
Construction of AAV hybrid helper plasmids. The genera-
tion of AAV serotype-specific hybrid helper plasmids utilized a
common AAV2 Rep gene pACG2 (25) and the respective
capsid coding sequences from each of the five serotypes (Fig.
1A). The ACG mutation of the p5 start site was chosen be-
cause this mutation has been shown to improve vector produc-
TABLE 1. Comparison of AAV helper constructs containing AAV2-only replication gene or
portions of the serotype specific replication genea
AAV2-only replication gene AAV2/serotype chimeric Rep
Serotype Particles/ml (n) Particles/ml (n)
rAAV1 1.27  1011 (10) ND
rAAV2 9.79  1012 (2) NA
rAAV3 9.00  108 (1) 7.16  1011 (3)
rAAV4 2.04  1010 (4) 2.63  1011 (2)
rAAV5 7.64  109 (1) 4.60  1011 (5)
rAAV5 with AAV5 ITR 0 3.70  107 (3)
a ND, not done; NA, not applicable.
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tion by reducing rep78/68 while increasing AAV cap expres-
sion (25). pACG2 rep sequences were cloned into pAAV2Cap
(Stratagene pBS backbone previously described [31]), and
the capsid gene was removed by SwaI/NsiI digestion. This
intermediate plasmid, pAAV2rep, was used for cloning each of
the serotype-specific capsid coding sequences (see Materials
and Methods for details). The capsid genes of each serotype
were PCR amplified from ATCC viral stocks, and the product
was cloned into this SwaI blunt-ended NsiI-digested
pAAV2rep intermediate. The new hybrid plasmids containing
the common AAV2 ACG replication gene and the serotype-
specific capsid sequences were further characterized by en-
zyme digestion and DNA sequencing. BstNI digestion (Fig.
1B) and DNA sequencing (data not shown) determined the
correct orientation and nucleotide sequence of the serotype-
specific capsid gene. When a number of independent isolates
for each serotype-specific helper were compared to traditional
type 2 helpers, vector yields varied significantly among these
constructs (Table 1). Surprisingly, additions of serotype-spe-
cific non-capsid-coding sequences (5 to the VP1 start site)
were required to reduce this variation (see Fig. 1, Table 1, and
Materials and Methods for further details). Additional analysis
(data not shown) suggests that a Rep-specific capsid interact-
ing domain is required for efficient serotype-specific encapsi-
dation (unpublished data). These constructs were designated
pXR1 to -5. Since these modified serotype-specific helper plas-
mids (as described in Fig. 1) produced vector yields within type
2 range (Table 1), they were further analyzed in detail for AAV
Rep and capsid production, as well as for the ability to repli-
cate AAV2 transgenes, as described below.
AAV hybrid helper functions. A series of experiments were
carried out on the pXR1 to -5 helper plasmids to determine
levels of type 2 rep- and serotype-specific capsid expression
after transfection in 293 cells. Western blot analysis was used
to detect the AAV rep gene products Rep78/68 and Rep52/40
(Fig. 2A) and the three capsid subunits Vp1, -2, and -3 (Fig.
2B) 24 h posttransfection. A comparison of AAV2 Rep pro-
teins in the context of different serotype helper plasmids was
carried out by using the monoclonal antibody 1F11 that rec-
ognizes each of the four AAV2 replication proteins (22). Pre-
vious studies demonstrated that the p5 mutation in the context
of the helper plasmid pACG-2 downregulated the expression
of Rep78/68, without affecting Rep52/40 (25). The results,
shown in Fig. 2A, demonstrate that in each of the serotype-
specific helper constructs all four Rep proteins were made at
levels equivalent to those described for the original AAV2
helper construct pACG-2 (25). With additional analysis, we
observed a lower level of Rep40 from the AAV4 helper con-
struct. The exact reason for this observation remains unknown.
The B1 monoclonal antibody (43), which recognizes the amino
acid recognition sequence IGTRYLTR in AAV2 structural
proteins (44), was used to identify the serotype-specific capsid
subunits. This motif is conserved in all serotypes except AAV4
(Fig. 2C), which is evident by the lack of positive signal after
Western analysis (Fig. 2B lane 4). For the other helper plas-
mids, all three capsid proteins were detected (Fig. 2B). Al-
though the data provided constitute a representative example,
we consistently observed higher amounts of the structural pro-
teins from serotype 1 compared to the other helper constructs
(repeated 10 times [data not shown]). Taken together, the
results for replication and capsid protein expression for the five
helper plasmids is within the range of AAV helper plasmids
currently available for production (14).
Replication and cross packaging of type 2 vectors. The func-
tional activities of these helper proteins were determined by
replication and encapsidation of the rAAV2 GFP template.
The five serotype helper plasmids, the rAAV2 transgene pTR/
CMV/GFP (packaging 3,400 bases), and the adenovirus helper
plasmid (pXX6-80) were triple transfected into 293 cells, and
Hirt analysis was carried out 24 h posttransfection. DpnI di-
gestion, followed by Southern blot analysis with GFP gene-
specific probe, determined the ratio of input plasmid to newly
replicated vector DNA. All serotype-specific helpers replicated
the vector template (Fig. 3, DpnI-digested lanes). Although
nearly equivalent amounts of input DNA were observed in all
lanes of undigested samples, replication of the transgene from
XR2, as determined by phosphorimaging, produced the high-
est levels (Fig. 3, lane 2). Repeated replication analysis dem-
onstrated that, while all other helpers were essentially equal,
XR1 consistently generated 40% of XR2 replication levels
(Fig. 3 lanes 7 and 8). Packaging efficiencies were determined
by dot blot hybridization (Table 1). All helper constructs gen-
erated high vector yields within 1011 to 1012 particles/ml. In
FIG. 2. Western blot of cell lysates from serotype-specific transfec-
tions. At 24 h after triple transfection, 5 g of total protein was loaded
into each well. After transfer the blots were incubated with the anti-
Rep monoclonal antibody 1F11, with the sizes of the proteins listed on
the right side (A), or the anticapsid monoclonal antibody B1, with the
capsid subunits listed on the right side (B). The serotype-specific help-
ers used in the transfection are listed above each blot. (C) B1 recog-
nition site as determined by Wobus et al. (44) is shown at the bottom
of the figure. The amino acid sequence from this region for all five
serotyes is shown. Asterisks indicate amino acids identical to those of
type 2.
794 RABINOWITZ ET AL. J. VIROL.
general, we observed that serotypes 1, 4, and 5 had yields
within fourfold of each other after numerous production runs
(five times), with serotypes 2 and 3 demonstrating the highest
yields (9.8  1012 and 7.2  1011, respectively [Table 1]). The
serotype 1 helper produced the least amount of virus (1.27 
1011 [Table 1]), a finding consistent with Hirt replication anal-
ysis.
Heparin column binding profiles of AAV hybrid serotypes.
The use of iodixanol gradient and/or heparin column binding
has allowed for the rapid purification of rAAV2 (1, 50). In,
addition, these methods allow for purification of vector with
better transducing to particle numbers. This purification
scheme was applied to the hybrid serotypes and elution profiles
determined by GFP transduction as described in Materials and
Methods.
Recombinant AAV2 demonstrated elution profiles as pre-
viously published (50), with 1% of starting material recov-
ered in the flowthrough and the majority of the TU being
recovered in the elution step (Fig. 4, AAV2). rAAV3 displayed
more efficient binding to the column and elution profiles nearly
identical to those of type 2. These results suggest that the
elution conditions used for rAAV2 purification can be applied
to the hybrid rAAV3. Recombinant AAV1 and -5 displayed
similar profiles to one another with 60% of type 1 and 80% of
type 5 TU recovered in the flowthrough (Fig. 4, AAV1 and -5).
The virus eluted from the salt gradient represents only a small
portion of the total applied to the column (Fig. 4, AAV1 and
-5). These data suggest that the heparin-Sepharose columns
are not suitable for the purification of rAAV1 or rAAV5.
The elution profile of rAAV4 was unique. Less than half of
the TU were recovered in the flowthrough, yet the majority of
TU were recovered in the elution step (Fig. 4, AAV4). These
results suggest that if the salt conditions were altered, virus
might be recovered in the elution step or that another ion-
exchange column might improve the recovery of AAV serotype 4.
Hybrid vector transduction on rodent, monkey, and human
cell lines. Various cell lines were infected with cesium gradi-
ent-purified hybrid vectors in an effort to determine the trans-
ducing titer in vitro (Fig. 5). Parental and mutant cell lines
defective in heparan sulfate proteoglycan biosynthesis were
analyzed for serotype-specific vector transduction since previ-
ous studies have demonstrated a role for this cell surface pro-
tein in type 2 infection. For rAAV1, a decrease in transduction
on CHO pgsD cells, which are heparan sulfate deficient, was
not observed. In fact, transduction efficiency for rAAV1 was
nearly identical for all cell lines tested (Fig. 5, AAV1). The lack
of specific binding to heparin columns and the ability to trans-
duce mutant heparan sulfate cell lines suggest that type 1 entry
is distinct from type 2 and yet to be identified. The transduc-
tion efficiency for rAAV2 and -3 were similar to what has been
previously published (17, 40), with each showing a dependence
on cell surface heparan sulfate (Fig. 5, AAV2 and -3) and
efficient binding to heparan sulfate columns (Fig. 4, AAV2 and
-3). Hybrid AAV5 transduction paralleled that of AAV1 for all
cell lines tested. After completion of these studies, evidence
identifying sialic acid as a cell surface molecule involved in type
5 transduction was published (23). The presence of sialic acid
on the battery of cell lines tested here was not determined,
although efficient transduction was observed. Hybrid vector
type 4 also transduced all cell lines tested. However, the level
FIG. 3. Hirt assay. Low-molecular-weight DNA was isolated from 293 cells, at 24 h after triple transfected with serotype-specific plasmids.
Then, 2.5 g of undigested (lanes 1 to 5) and DpnI-digested DNA (lanes 7 to 11) from each serotype sample was loaded onto a 1% agarose gel
(lane 6, DNA ladder). After transfer the blot was probed with a 735-bp fragment of the GFP gene. Input DNA digested with DpnI reveals the
replicating monomer and dimer transgene (arrowed). The lower bands in lanes 7 to 11 are DpnI digestion products of input plasmids.
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FIG. 4. Transduction efficiency of fractions off a heparin-Sepharose affinity column for rAAV serotypes 1 through 5. The elution conditions
were optimized originally for AAV2 (50). Numbered fractions were collected in 0.5-ml volumes, waste (W) was collected in a single 10-ml fraction,
and the control (C) was a 1-ml aliquot of virus applied to the column. Infections were done in reference cell lines, with between 1/100 to 20 l
of each fraction. Salt elution began with fraction 26. Each bar represents the average of three separate infections, with the standard deviation
indicated by an error bar.
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of transduction never approached that observed on monkey-
derived cell lines (Fig. 5, AAV4). The restriction in the in vitro
host range that has been observed with both the hybrid and the
traditional type 4 vectors (data not shown) suggests that effi-
cient transduction requires a monkey-specific factor. Overall,
these results suggest that, unlike types 2 and 3, AAV1, -4, and
-5 do not require heparan sulfate for infection. These obser-
vations are in agreement with other studies evaluating the
transduction requirements of non-AAV2 serotypes (8, 9, 46)
and demonstrate the influence of the serotype-specific virion
shells on vector transduction.
Hierarchy of gene expresssion for AAV hybrid vectors in
vivo. The efficiency of gene expression of both therapeutic and
marker transgenes were tested when delivered by each of the
five hybrid vectors in vivo. The expression of human 1-anti-
trypsin (hAAT) and factor IX were tested in outbred and
inbred mice, as well as immunodeficient mouse lines (Table 2).
The hAAT expression was also examined with respect to the
route of injection (i.e., portal vein, intramuscular, and intrave-
nous) (Table 2). ELISA was used to monitor expression of the
therapeutic transgenes which consistently demonstrated that
AAV1 was superior to the other hybrid vectors tested. This
observation was true for all strains of mice, routes of admin-
istration, or transgenes tested (Table 2). However, we did
observe small differences in the efficiency of expression for the
remaining serotypes with respect to each variable. For exam-
ple, of the five serotypes tested, the rAAV4 vector was the least
efficient in the expression of hAAT. In contrast, the rAAV2
vector was the least efficient in the expression of factor IX.
These observations point to the importance of evaluating spe-
cific transgene and cis-acting regulatory sequences when cer-
tain serotype-specific virions for efficient trandsuction are com-
pared.
Evaluation of AAV serotypes gene transfer efficiency in the
rat retina. Previous studies have shown type 5 transduction to
be more efficient in the brain compared to type 4 or 2 (11). In
our study, type 1 vector appeared to be superior to all the
others when tested in non-neuronal targets. We extended our
hybrid vector analysis to neuronal targets by using rat retina as
a substrate and GFP as a reporter. Each of the five serotype
vectors was determined for efficient in vivo transduction by
using fundus color photography after subretinal injections. At
12 days postinjection, GFP expression could be detected in
rAAV5, -4 and -1-injected animals, with type 5 and 4 hybrids
displaying the most intense GFP signal. No signal was detected
in animals injected with rAAV2 or -3 at this concentration and
time point (Fig. 6). At 26 days postinjection, GFP expression
increased proportionally for rAAV5, -4, and -1, with types 2
and 3 eventually displaying a small but positive signal (Fig. 6,
26 days). This trend continued for up to 46 days (Fig. 6, 46
days), and these animals remained positive for the duration of
the experiment (4 months). We also observed cell type-specific
tropism when we used these hybrid vectors in the retina. The
FIG. 5. Transduction efficiency in CHO mutant and reference cell lines. Cells (cell types are specified in the legend on the right) were
transduced with ca. 0.3 TU/cell, as determined by the reference cell lines (HeLa cells for AAV serotypes 1, 2, 3, and 5 and Cos1 cells for AAV4).
The transducing titers are given for each serotype in each cell line. The particle numbers used in this experiment (per microliter) were as follows:
rAAV1, 1.2  108; rAAV2, 5.6  108; rAAV3, 9.1  108; rAAV4, 2.3  108; and rAAV5, 5.4  108. Each bar represents the average of three
separate infections, with the standard deviation indicated by an error bar.






AAV1 AAV2 AAV3 AAV4 AAV5
hAAT C57BL (i.m.)     
C57BL (p.v.)     
C57BL (i.v.)     
BALB/c (i.v.)     
dF9 Scid (i.m.)     
BALB/c (i.m.)     
a The transgenes were chicken -actin promoter with the CMV enhancer-
driven hAAT (both C57/BL and BALB/c mice were at 5  1010 particles/mouse)
and CMV immediate-early promoter-driven dog (d) factor IX (SCID mice at 2 
1011 particles/mouse and BALB/c mice at 1010 particles/mouse).
b For each group of animals, serotype, and route of injection a minimum of
three animals were used. i.m., intramuscular injection; p.v., portal vein injection;
i.v., intravenous injection.
c Scores ranged from the maximum level of protein observed for each set of
animals () to the lowest level of expression in the group ().
VOL. 76, 2002 CROSS-PACKAGING OF A SINGLE AAV2 VECTOR GENOME 797
798 RABINOWITZ ET AL. J. VIROL.
exact mechanism and cell types being transduced are being
investigated. These results may be significant when an appro-
priate vector is chosen for a specific disease and also demon-
strate, in addition to efficiency, features that may be advanta-
geous when serotype-specific hybrid vectors are used.
Based on these observations, a different hierarchy of sero-
type-specific transgene expression was observed in retina com-
pared to non-neuronal tissues. In this setting, serotypes 5 and
4 were superior, followed by types 1, 2, and 3 (Fig. 6). Low to
moderate levels of expression from AAV1 was in sharp con-
trast to data obtained in non-neuronal tissue. However, we
cannot distinguish whether these differences are due to prop-
erties associated with the virions or simply species differences
between rats and mice. Based on AAV2 transduction now
established in rodents, dogs, rabbits, and monkeys, it is unlikely
that the hybrid vector transduction efficiencies are species re-
lated, although additional nonrodent experiments will be re-
quired to completely rule out this concern. Taken together, the
expression of therapeutic and marker genes from the five hy-
brid serotypes demonstrates that AAV1 is the superior vehicle
for non-neuronal delivery, while in the retina and in the brain
(11) AAV5 produces the highest levels of marker gene expres-
sion. All in all, these data demonstrate the importance of
determining serotype-specific transduction in vivo when AAV
is being considered as the delivery system of choice.
DISCUSSION
The serotypes of AAV have the potential to become impor-
tant resources for clinical gene therapy. In an effort to compare
the role of serotype-specific virion shell on vector transduction,
we cloned each of the serotype capsid coding domains into a
common vector backbone containing AAV2 replication genes.
This strategy allowed the packaging of AAV2 ITR vectors into
each serotype-specific shell. We reasoned that it would not be
uncommon to expect each of the serotype-specific cis-acting
terminal repeats to have unique influences on transgene ex-
pression. In support of this concept, the potential to alter
transgene specific promoter activity with ITR elements both in
vitro and in vivo has been observed (12, 15). Therefore, we
chose the AAV2 ITRs for our common cis-acting vector se-
quences since these elements are best understood of the five
serotypes. Using type 2 vectors and the hybrid AAV helper
strategy described above, we in effect normalized the contri-
bution of cis-acting sequences on vector transduction. We also
focused only on AAV serotypes 1 to 5 shells since immuno-
logical studies have now determined that AAV1 and -6 are
indistinguishable (C. Li et al., unpublished data). In addition to
determining the role of the hybrid capsid shell in vector trans-
duction, this approach has facilitated an effort for standardiz-
ing AAV serotype-specific vector production. Based on this
strategy, similar studies can now be carried out to determine
the role of serotype-specific cis-acting ITRs (i.e., type 5 ITRs in
AAV1 to -5 shells). The outcome of such studies may deter-
mine still more features and combinations of hybrid vectors
that enhance or influence efficient transduction. These combi-
nations will be important in determining the best AAV-derived
delivery reagent for use in humans.
Our initial analysis of AAV3, -4, and -5 hybrid helper con-
structs resulted in reduced ability to generate high-titer vec-
tors. Recent studies have demonstrated that the first 232 amino
acids of AAV2 rep is required for origin specific binding when
the AAV2/Goose parvovirus rep chimera is used (48). With
respect to the type 5 hybrid construct, we were able to use as
few as the first 250 amino acids of AAV2 rep to efficiently
replicate and package rAAV2 ITR containing templates into
type 5 virions. These results suggest that sequences down-
stream of the Rep78/68 DNA-binding domain are required for
efficient encapsidation. In support of this concept, previous
studies have shown that the small Rep proteins have helicase
activity (38) and that this activity is required for efficient pack-
aging of the viral genome into preformed capsids (24). There-
fore, we would predict that inclusion of serotype-specific small
Rep proteins would be sufficient for efficient encapsidation.
Our results are consistent with this hypothesis, because substi-
tution of AAV5 sequences downstream of the BamHI site in
pXR5 dramatically increased virus production. Similarly, sub-
stitution of AAV3 and AAV4 sequences downstream of the
AccI site in pXR3 and pXR4, respectively, improved virus
production 10- to 1,000-fold. Because these sequences all lie
downstream of the p19 promoter within coding sequences
shared between the large Rep proteins and the small Rep
proteins, their effect on DNA encapsidation may be due to
domain in the small Rep proteins that interacts with the cap-
sids in a sertotype-specific manner (unpublished data). Due to
high sequence similarity between type 2 and 1 rep sequences,
no additional modification were made to this helper construct.
Our vector yields with this hybrid helper were in agreement
with that generated from type 1 helper constructs only (data
not shown; see also reference 46).
The ability to produce recombinant virus depends on the
function of the replication and capsid proteins. Protein analysis
demonstrated that nearly equivalent amounts of Rep proteins
were generated for all of the serotypes. With respect to capsid
proteins, rAAV1 and -5 consistently expressed higher levels
(Fig. 2B, lanes 1 and 5). We were unable to assess the AAV4
capsid due to the absence of antibody recognition epitope (Fig.
2B, lane 4, and C). Previous studies have suggested a delicate
balance between replication, capsid proteins, and efficient
packaging (25, 42). We did not observe a correlation between
capsid level and vector yield; instead, the level of virions pro-
duced tracked more closely with transgene replication (Fig. 3).
This was most obvious with type 1 helper (Fig. 3 and Table 1).
FIG. 6. Subretinal injection and in vivo fluorescence imaging. Subretinal injections were performed via a transcleral transchoroidal approach
on wild-type Wistar rats, as previously described (33). Briefly, the sclera and the choroid were punctured, and a 33-gauge needle was then inserted
in a tangential direction under an operating microscope. Three microliters of each of the five rAAV serotypes (5  1010 particles/ml) was delivered
into the subretinal space of rats (n  3). A new method using fundus photography has been developed and was performed here in order to control
the accuracy and reproducibility of subretinal injections (Rolling et al., unpublished). GFP protein expression in live rats was monitored by
fluorescent retinal imaging with a Canon UVI retinal camera connected to a digital imaging system (Lhedioph Win Software). Retinas were
examined at 12, 26, and 46 days postinjection.
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Although vector replication appeared to be uniform for helper
constructs 2 to 5, type 1 was consistently lower (40% of type 2).
These differences were observed in multiple experiments and
are difficult to explain since the vector ITR and Rep proteins
are all type 2 derived.
Regardless of the vector yields, these new helper constructs
allowed for further examination with respect to virion purifi-
cation and influence of serotype-specific virion shell on trans-
ducing titer in vitro and in vivo.
The ability to bind heparan sulfate has changed the method
of choice for AAV2 purification from cesium chloride isopyc-
nic centrifugation, which has been shown to damage AAV2, to
column chromatography (1, 40, 50). These methods have re-
sulted in lower ratios of particles to transducing numbers and
may have application to the other serotypes. Using heparin
column purification conditions, we determined that AAV2 and
-3 could be efficiently purified by heparin-Sepharose column
chromatography with 	91% of the TU being recovered (Fig.
4). In contrast, 1% of AAV1 and -5 were recovered during
the elution step. Interestingly, with respect to type 1 binding,
Wu et al. (45) described two substitution mutants in the AAV2
capsid that resulted in amino acid changes which lost heparan
column binding, of which the first was located between amino
acids 561 to 565 DEEEI and is conserved in AAV1. The
second change (from positions 585 to 588, i.e., RGNR) is SSST
in AAV1, suggesting that both or either of these may be re-
sponsible for loss of heparan sulfate binding. With respect to
AAV5, recent studies have determined that sialic acid serves as
a receptor for vector transduction, providing a reason for lack
of heparan sulfate binding. AAV4 did not demonstrate any
specific binding with the heparan sulfate columns based on
elution profiles but appears to interact more strongly with the
column matrix, as evidenced by the relatively large recovery of
TU in the flowthrough, wash, and waste. Although it does not
appear that either AAV1 or -5 will be efficiently purified with
the heparin-Sepharose column, if binding conditions for
AAV4 were altered it may be possible to purify this serotype by
heparin chromatography. Our results suggest the need for a
universal purification system, potentially based on ion-ex-
change chromatography; however, for in vitro and in vivo
transduction analysis, we relied on conventional CsCl purifi-
cation.
Reference cell lines were used to establish the titers of the
serotypes. We defined these as cell lines that consistently
showed high levels of transduction, ease of counting, good
plating efficiency, and consistent susceptibility to helper virus
coinfection. HeLa cells were used as the reference cell line for
four of the serotypes—AAV1, -2, -3, and -5—and Cos1 cells
for AAV4. Using the titers established in the reference cell
lines as a guide, we transduced cell lines defective in proteo-
glycan biosynthesis to determine the vector proteoglycan bind-
ing properties (40). Consistent with heparan sulfate column
affinity, AAV serotypes 2 and 3 showed a dependence on
heparan sulfate proteoglycans for efficient transduction, as pre-
viously observed (17, 40). Interestingly, both serotypes showed
nearly equivalent changes (	1,000 times) in susceptibility to
transduction when the mutant CHO pgsD and HeLa cell line
titers were compared (Fig. 5, AAV2 and -3, CHO pgsD versus
HeLa). When the mutant to parental CHO lines were evalu-
ated, we observed a 10- to 25-fold change in transduction (Fig.
5, AAV2 and -3, CHO K1 versus CHO pgsD). Based on this
analysis, the CHO cell appears to be suboptimum for AAV2
and -3 vector transduction, suggesting that additional step(s)
may be required. This is not the case for type 1 and 5 virions.
Originally, it was thought that AAV1 bound heparan agarose
(31); however, the transduction efficiency in CHO pgsD cells
was only fivefold less than the reference cell line and threefold
more efficient than the CHO K1 line (Fig. 5). In contrast,
AAV4 and AAV5 do not show a dependence on heparan
sulfate for transduction (Fig. 5), where the CHO mutant lines
were transduced better than or the same as the parental CHO
K1 line, respectively. The serotypes show preferences in vitro
for transduction of specific cell lines (Fig. 5), so we then as-
sayed these reagents in vivo to further define vector perfor-
mance.
Based on recent studies, a hierarchy for both qualitative and
quantitative expression of AAV serotype vectors is being elu-
cidated (6, 11, 46, 49). In our experiments, we determined that
AAV1 was superior in liver and muscle. In contrast, others
have reported that AAV2 was more efficient than AAV1 in
transducing the liver (46). At present we do not have a simple
explanation for this discrepancy, but we have now tested nu-
merous routes of administration and various transgenes that
consistently result in superior expression from type 1 vectors in
the liver (Table 2). Interestingly, we observe a change in the
order of efficient transduction when hybrids were tested in
neuronal tissue. Expression from rAAV5 has been shown to be
most efficient in the brain compared to types 2 and 4, and our
studies have now determined that this is also true for retina
(11, 49) (see also Fig. 6). Surprisingly, we observed that type 4
expression in the retina was far more efficient than that of type
1, 2, or 3. This observation appears to be distinct compared to
brain and other non-neuronal tissue (Fig. 6 and Table 2) (7, 11,
49). All of these data begin to support the need for additional
studies analyzing serotype-specific vector distribution before
we can extrapolate conclusions to other animal models or
humans. For diseases such as diabetes, cystic fibrosis, muscular
dystrophy, Alzheimers, and cancer, etc., the transgene target
may become an important component when one is determining
which serotype shell to use. Previous analysis of type 2 trans-
duction in animal models translated from rodent, to canine, to
nonhuman primate (29) and have now been extended in hu-
mans through a phase I safety trial (19). If serotype-specific
vectors have similar attributes, then the results of this study
strongly suggest that hybrids AAV1 and -5 are superior deliv-
ery agents for non-neuronal and neuronal targets, respectively.
The serotypes of AAV have the potential to become pow-
erful tools for safe gene delivery to the target of interest. The
ability to better compare and contrast that potential will allow
for a more considered choice of delivery reagent for specific
gene therapy applications. These plasmids represent the first
set of AAV serotype helpers that can be used in this way. The
construction of five serotypes in the same genetic backbone,
packaging an identical transgene with common serotype ITRs,
will now provide researchers the ability to make these compar-
isons.
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